Zacks: Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC) Given Average Rating of “Strong Buy” by Analysts

Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC) has earned an average broker rating score of 1.00 (Strong Buy) from the three brokers that provide coverage for the company, Zacks Investment Research reports. Three analysts have rated the stock with a strong buy rating.

Analysts have set a 1 year consensus target price of $7.00 for the company and are predicting that the company will post ($0.15) EPS for the current quarter, according to Zacks. Zacks has also assigned Cyclacel Pharmaceuticals an industry rank of 64 out of 256 based on the ratings given to related companies.

CYCC has been the subject of a number of recent research reports. HC Wainwright reissued a “buy” rating on shares of Cyclacel Pharmaceuticals in a research report on Wednesday, May 15th. Roth Capital reissued a “buy” rating on shares of Cyclacel Pharmaceuticals in a research report on Thursday, May 23rd. Finally, Zacks Investment Research cut shares of Cyclacel Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, July 16th.

Shares of NASDAQ:CYCC traded up $0.02 on Friday, hitting $0.57. The company had a trading volume of 1,808 shares, compared to its average volume of 71,034. Cyclacel Pharmaceuticals has a 1 year low of $0.51 and a 1 year high of $1.87. The company has a market cap of $9.61 million, a price-to-earnings ratio of -0.93 and a beta of 2.94. The stock’s 50-day moving average is $0.56. The company has a quick ratio of 8.09, a current ratio of 8.09 and a debt-to-equity ratio of 0.08.

Cyclacel Pharmaceuticals (NASDAQ:CYCC) last issued its quarterly earnings results on Tuesday, May 14th. The biotechnology company reported ($0.15) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.04. As a group, research analysts forecast that Cyclacel Pharmaceuticals will post -0.63 EPS for the current fiscal year.

Cyclacel Pharmaceuticals Company Profile

Cyclacel Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's oncology development programs include CYC065, a cyclin dependent kinase Inhibitors (CDK) that is in Phase I clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and CYC140, a polo-like kinase inhibitor program, which is in Phase I clinical trial for the treatment of advanced leukemias.

Read More: When can a hold rating present a buying opportunity?

Get a free copy of the Zacks research report on Cyclacel Pharmaceuticals (CYCC)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Cyclacel Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cyclacel Pharmaceuticals and related companies with's FREE daily email newsletter.